Welcome to our dedicated page for Eli Lilly and news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Eli Lilly and stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Summary not available.
The FDA has granted Breakthrough Therapy designation for Jardiance (empagliflozin) for treating adults with heart failure with preserved ejection fraction (HFpEF). This follows promising results from the EMPEROR-Preserved trial, showing a 21% relative risk reduction in cardiovascular death or hospitalization. Jardiance is already approved for heart failure with reduced ejection fraction. HFpEF affects around 3 million adults in the U.S., with no proven treatment options available until now.
Eli Lilly has pledged nearly $1 million over three years in collaboration with the Helmsley Charitable Trust to enhance access to resources for children with type 1 diabetes (T1D). This initiative aims to provide camperships for low-income youth, ensuring inclusivity in diabetes camps nationwide. The funding will also assist camps in adapting to COVID-19 requirements. Lilly's long-term commitment to diabetes care emphasizes equity and improved access for communities, reflecting its ongoing mission to better lives affected by diabetes.
Eli Lilly and Company (NYSE: LLY) has initiated a cash tender offer for up to $1.5 billion of its outstanding debt securities. The offer includes various notes with different due dates and interest rates, such as the 4.150% Notes due 2059 and 3.950% Notes due 2049, among others. The early tender deadline is set for September 20, 2021, with the final expiration on October 4, 2021. Holders must tender their notes to receive an early tender premium and are subject to certain limitations outlined in the Offer to Purchase.
Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021. Michael Mason, Lilly's Senior Vice President and President of Lilly Diabetes, will engage in a virtual fireside chat at 1:15 p.m. Eastern Time. A live audio webcast of the event can be accessed on Lilly's Investor website, with a replay available for approximately 90 days. Lilly, a global healthcare leader, is dedicated to developing life-changing medicines and enhancing disease management.
Eli Lilly and Company (NYSE: LLY) will participate in Citi's 16th Annual BioPharma Virtual Conference on September 8-9, 2021. Senior Vice President and CFO Anat Ashkenazi will speak at a virtual fireside chat on September 9 at 9:45 a.m. ET. A live audio webcast will be available on Lilly's Investor website, with a replay accessible for about 90 days. Founded over a century ago, Lilly is committed to creating high-quality medicines and improving disease management globally.
Eli Lilly and Company (NYSE: LLY) announced the resignation of Carolyn R. Bertozzi, Ph.D., from its board of directors effective August 25, 2021. Her departure is linked to Lilly's collaboration with Lycia Therapeutics, Inc., where she is an academic founder. Bertozzi has served on the board since 2017, contributing her scientific expertise to Lilly's innovative pipeline. The CEO expressed gratitude for her service, highlighting her influence on technical and ethical decisions.
Eli Lilly and Company (NYSE: LLY) has entered a strategic collaboration with Lycia Therapeutics to discover and develop targeted therapeutics using Lycia's LYTAC technology. The partnership will focus on up to five targets in key areas like immunology and pain, addressing unmet medical needs. Lycia will receive an upfront payment of $35 million and may earn over $1.6 billion in milestone payments and royalties. Lilly is responsible for the development and commercialization of potential therapies, with no immediate impact on its 2021 earnings guidance.
The U.S. FDA has approved Jardiance (empagliflozin) 10 mg for reducing the risk of cardiovascular death and hospitalization in adults with heart failure with reduced ejection fraction (HFrEF). This decision is based on the EMPEROR-Reduced trial, where Jardiance demonstrated a 25% reduction in cardiovascular death or hospitalization risk compared to placebo. Jardiance is contraindicated for those with type 1 diabetes and severe kidney issues. The approval marks a significant advancement in treatment options for heart failure patients.
Eli Lilly and Company (NYSE: LLY) announced executive leadership changes and the formation of neuroscience and immunology business units effective September 5, 2021. Anne White will lead Lilly Neuroscience, focusing on pain and neurodegeneration, including the potential launch of donanemab for Alzheimer's. Jacob Van Naarden now serves as CEO of Loxo Oncology and president of Lilly Oncology. Patrik Jonsson will head Lilly Immunology. Changes aim to enhance focus on breakthrough therapies for unmet medical needs. Alfonso Zulueta will retire; Ilya Yuffa will succeed him.